Autopsy report · NCT02658396

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

“Study was never open due to lack of funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Dana-Farber Cancer Institute

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma; Multiple Myeloma in Relapse; Refractory Multiple Myeloma

Interventions

GO-203-2C; Bortezomib

Participants

0

Sites

2

Countries

United States

Trials that died the same way

• Angiotensin 2 for Hepatorenal Syndrome
  “Funding issues; the study was never started” (85% match in meaning)
• Regulation of the Release of Inflammatory Mediators From Blood Leukocytes
  “No funding for the study” (84% match in meaning)
• Vasomotor Symptoms and Cardiovascular Control
  “No funding obtained to conduct study” (83% match in meaning)
• Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19
  “The study did not get financed. Never got started.” (82% match in meaning)
• L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder
  “Study funding has not been established” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.